

Haematologica
HAEMATOL/2018/191650
Version 3

MDM2- and FLT3-inhibitors in the treatment of FLT3-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin

Katja Seipel, Miguel A.T. Marques, Corinne Sidler, Beatrice U. Mueller,
and Thomas Pabst

Disclosures: 1. Novartis provided the investigational compounds NVP-HDM201 and NVP-CGM097. 2. The authors declare no potential conflicts of interests.

Contributions: K.S. designed, performed and supervised research, acquired, analyzed and interpreted data, performed statistical analysis and wrote the manuscript; M.T.M. and C.S. performed research; B.U.M. analyzed data; T.P. designed research, analyzed data and wrote the manuscript. All authors read and approved the report in its final version.